I remember hearing about Joe Rogan when he got COVID. He took everything under the sun, monoclonal antibodies, Zpack, and Ivermectin. This set the media off on Joe, calling Ivermectin “horse paste” and all sorts of bad names. Tim Pool, another Youtube host contracted COVID-19. Joe Rogan sent him the protocol he used. Tim got better just as fast as Joe Rogan. Two of Joe Rogan’s guests, Robert Malone, inventor of the mRNA vaccine, and Peter McCullough, the most published medical doctor ever, were pilloried for objecting to the mainstream media and the CDC’s recommendations for treating COVID-19. Because it didn’t fit with the CDCs plans for COVID and the mRNA vaccines. The anti-viral mRNA is not really a vaccine because “the vaccine” is only effective against COVID-19 for up to six months. After that, you’re on your own. Natural immunity, which the CDC is finally recognizing as effective against COVID-19, lasts for up to 24 months. Natural immunity is something you already have or it results from recovering from COVID-19. McCullough in his interview with Joe Rogan stated that Ivermectin could have saved 500,000 lives in the U.S. alone. Let that sink in.
Two large peer-reviewed studies just came out evaluating the efficacy of Ivermectin. The first study (Efiimenka, et. al., Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of a National Federated Database, International Journal of Infectious Diseases, March 2022, compared survival rates for Remdesivir and Ivermectin. Remdesivir is another experimental anti-viral that costs about $440/vial. A known side effect of Remdesivir is acute kidney failure. Ivermectin costs pennies per pill. Strangely, over 25,000 COVID-19 patients died of acute kidney failure in New York City because part of their protocol was to administer Remdesivir to patients with COVID-19. Doctors thought it was strange that people coming in with a respiratory illness died of kidney failure.
Update. 3/12/2022 – the above paper was withdrawn the other day. There is no indication as to why the paper was withdrawn. I suspect it is the comparison with the much more expensive Remdesivir and the negative side-effects of kidney (renal) failure brought to light. If I find out more I will bring it to light.
This study took data from 44 health institutions involving potentially some 68 million patients. The protocol for the study controlled for, comorbidities, and treatments that may affect COVID-19 survival outcomes: age, gender, race, ethnicity, nicotine use diabetes mellitus, obesity, chronic lower respiratory disease, ischemic heart diseases, tocilizumab, glucocorticoids, or ventilator use.
This study involved 41,608 patients who had COVID-19. The number treated with ivermectin n = 1,072 vs those treated with Remdesivir n = 40,536. The study showed that a patient was 70% less likely to die taking Ivermectin vs Remdesivir. The p-value for this study was 0.0001 meaning that the likelihood that the results were chance is 1 in 10,000. Very small indeed. Most statistical analyses are acceptable with a p-value of 0.05 or 1 in 20.
The second paper by Kerr L, Cadegiani F A, Baldi F, et al. (January 15, 2022) Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching. Cureus 14(1): e21272. doi:10.7759/cureus.21272. In this study, they invited the entire population of Itajaí, Brazil (pop. 223,128) to enroll in the program. Of the city’s population, 159,561people were included in the analysis where 113,845 (71.3%) were regular ivermectin users and 45,716 (23.3%) non-users. The regular use of ivermectin led to a 68% reduction in COVID-19 mortality.
The protocol for administering Ivermectin involved “in the absence of contraindications, ivermectin was offered as an optional treatment to be taken for two consecutive days every 15 days at a dose of 0.2 mg/kg/day.” Note this is an extremely small dose of Ivermectin.
During the period of this study, July 2020 – December 2020 the following occurred: in the Ivermectin group there were 25 deaths (0.8%.) In the Non-Ivermectin group, there were 79 deaths (2.6%.) The p-value for this study was also 0.0001. When adjusted for residual variables, the reduction in mortality rate was 70% lower in the group taking Ivermectin. There was also a 56% reduction in hospitalization rates for those taking Ivermectin (44) vs 99 for the non-Ivermectin.
Clearly, with little to no known side effects, prophylactic use of Ivermectin, even ins very small doses is very effective against COVID-19. And, with the cost of Ivermectin being almost trivial, how hard would it have been to give those groups most at risk Ivermectin as a preventative measure? If you know someone with COVID-19, get them some Ivermectin, immediately. It could save their life.